3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)

Primary care, Mental Health & Long-Term Care

08:00 am
01 Oct, 2025
etc.venues, Prospero House, 241 Borough High St, London SE1 1GA

3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)

Primary care, Mental Health & Long-Term Care

08:00 am
01 Oct, 2025
etc.venues, Prospero House, 241 Borough High St, London SE1 1GA

Overview:

The iPAM® is a congregation for delegates to attend and share ideas of good medical practice and latest evidence-based interventions in the field of psychiatry and addiction.

The 1st iPAM ® was delivered as a virtual conference during Covid 19 pandemic on 14th and 15th November 2020 from Dubai, UAE. We had hundreds of registrations from across five continents. Approximately a hundred questions were asked and answered during the two-day sessions and on an average 90% of the attendees rated the content, session and faculty from very good to excellent.

The 2nd iPAM ® was delivered on the 15th October 2021 in Dubai, UAE as a hybrid event and our speakers presented their expert views on the current evidence around various themes related to mental health, addiction, psychological interventions, interface of mental health with physical health and emerging trends in psychiatry. It was a resounding success.

The 3rd iPAM will be successfully organised on the 1st of October 2025 in London, UK. We have excellent speakers delivering their expert views over various topics. Our faculty will be delivering their sessions from the UAE, United Kingdom, United States of America and from other GCC countries.

Who Will Attend:

Each year iPAM ® will develop new and upcoming themes which will be deemed necessary and useful for the attending delegates.

  • Doctors- Psychiatrists, GPs, Hepatologists etc.
  • Psychologists
  • Any HCP working in the field of psychiatry and addiction.
  • Nurses
  • Social workers

Speakers

David Nutt FMedSci

Imperial College London

Psychiatrist and Prof of Neuropsychopharmacology

Devon De Silva

Via

Innovation and Research Unit Manager

Dr Baxi Sinha

TEWV NHS Foundation Trust

Consultant Psychiatrist & Lead, Ketamine Service for TRD Deputy Medical Director (IR)

Dr Cyrus Abbasian

Private Digital Psychiatrist

Consultant Psychiatrist

Dr Hasanen Al-Taiar

The Oxford Clinic, Littlemore Mental Health Centre

Consultant Forensic Psychiatrist Forensic TPD. Medical Member HM Tribunal Service

Dr Louise Sell

Pennine Care NHS Foundation Trust

Consultant Psychiatrist

Prof Yasir Abbasi

Via

Executive Medical Director and Consultant Psychiatrist

Professor Cathy Montgomery

Liverpool John Moores University

Professor of Psychopharmacology & Health Inequalities; Head of Institute for Health Research

Sponsors & Partners

The programme

08:00

Registration

Registration

09:00

Introducing the 3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)

Prof Yasir Abbasi
Executive Medical Director and Consultant Psychiatrist
Via

Introducing the 3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)

Chair: Dr Shahid Latif

 

09:15

Ketamine infusion for treatment resistant depressive disorder (Confirmed)

Dr Baxi Sinha
Consultant Psychiatrist & Lead, Ketamine Service for TRD Deputy Medical Director (IR)
TEWV NHS Foundation Trust

This presentation captures real-world experience from the NHS in implementing Ketamine treatment for Treatment-Resistant Depression. Sharing treatment protocols, it highlights how a motivated team, working within the constraints of limited resources, established and sustains an innovative service that is making a positive difference in clinical outcomes.

09:35

Ketamine Addiction - Should we be concerned?

Speaker:

Dr Arun Dhandyudham

10:15

Can we manage psychotropic induced metabolic syndrome with GLP1 medications

Speaker:

Dr Naveed Younis 

 

10:35

Q&A

Q&A

10:50

Tea Break and Networking

Tea Break and Networking 

11:50

Chair Morning Reflections (Confirmed)

Dr Louise Sell
Consultant Psychiatrist
Pennine Care NHS Foundation Trust
Dr Louise Sell, Consultant Psychiatrist, Pennine Care NHS Foundation Trust (Confirmed)

11:55

AuDHD - What is behind the diagnosis?

Speaker:

Dr Khurram Saddiq 

12:15

Does addiction present differently in people with Neurodiversity? (Confirmed)

Dr Cyrus Abbasian
Consultant Psychiatrist
Private Digital Psychiatrist

As clinicians, we are increasingly recognising and developing competencies in identifying and managing neurodiversity-related conditions, particluarly adult ADHD and autism. Individuals with a dual diagnosis—neurodiversity co- occurring with other mental health conditions such as addictions—pose a distinct set of clinical challenges. Their addictive behaviours, whether substance-related or behavioural (e.g. problem gambling, gaming, internet use, social media, or smartphone overuse), may present atypically and often prove more resistant to conventional treatment approaches.

This presentation explores the complexities of such dual diagnosis cases, with a focus on both substance misuse and the growing recognition of behavioural addictions. It underscores the need for mental health services to adapt and provide responsive, neurodiversity-informed care pathways.

12:35

Forensic Aspects of Addiction Psychiatry: Risk, Responsibility, and Rehabilitation (Confirmed)

Dr Hasanen Al-Taiar
Consultant Forensic Psychiatrist Forensic TPD. Medical Member HM Tribunal Service
The Oxford Clinic, Littlemore Mental Health Centre

  1. Culpability and Criminal Responsibility in Addicted Offenders 
    An exploration of how substance misuse disorders impact mens rea (criminal intent), including the legal frameworks of diminished responsibility, insanity, and automatism. Case law and practical examples will be discussed to illustrate the role of expert psychiatric evidence in court. 

  1. Addiction, Risk, and Recidivism in Forensic Populations 
    A detailed examination of how addiction contributes to violence, acquisitive crime, and sexual offending in forensic settings. This section will include an overview of validated tools used to assess risk in offenders with comorbid addiction and mental illness. 

  1. Rehabilitation and Risk Management of Offenders with Addiction 
    Discussion of evidence-based treatment models (e.g. dual diagnosis pathways, trauma-informed care, and therapeutic jurisprudence) in secure settings and prisons. The presentation will also cover the medico-legal challenges of managing addiction within the forensic framework, including issues of consent, capacity, and long-term risk. 

12:55

Q&A

Q&A

13:10

Networking and Lunch

Networking and Lunch

13:55

Chair Afternoon Address

Chair:

Dr Emily Finch

14:00

Gaming Disorder in the UK: an overview

Speaker:

Prof Henrietta Bowden-Jones

14:20

The Royal college of psychiatrists - the challenges of international work

Speaker:

Prof Mohammed Al Uzri 

14:40

Developing addiction psychiatry training and wokforce

Speaker:

Prof Subodh Dave 

15:00

Cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder (Confirmed)

Professor Cathy Montgomery
Professor of Psychopharmacology & Health Inequalities; Head of Institute for Health Research
Liverpool John Moores University
Devon De Silva
Innovation and Research Unit Manager
Via

Long-Acting Injectable Buprenorphine is a recent advance in the treatment of opioid use disorder which can be administered in weekly or monthly injections, allowing people with opioid use disorder to engage with daily activities without the need or daily supervised consumption. However, there is little research on the how and why this treatment may be beneficial compared to standard of care.

This talk discusses a study where we compared self-reported outcomes for people who are prescribed Long-Acting Injectable Buprenorphine compared to other medications for opioid use disorder. We used logistic regression to identify predictors of being prescribed LAIB compared to other medication for opioid use disorder, and we compared changes in self-reported physical health, mental health and quality of life over a one-year period. We contextualised the results with qualitative interviews with people with opioid use disorder and clinicians.

15:20

Q&A

Q&A

15:35

Psychedelic assisted treatments- what the future holds and Q&A

David Nutt FMedSci
Psychiatrist and Prof of Neuropsychopharmacology
Imperial College London

Speaker:

Prof David Nutt

Chair:

Dr Khansa Nabil

16:10

Closing remarks for the 3rd iPAM

Prof Yasir Abbasi
Executive Medical Director and Consultant Psychiatrist
Via

Closing remarks for the 3rd iPAM

16:15

Networking Drinks

Networking Drinks

17:00

End of Conference

End of Conference

Book tickets

Ticket
Price
Quantity
Standard Registration Fee (In-Person)
£180.00 excl VAT
Limited places
0

Our accreditations

abpco 2021
Manchester Bee
CPD Member
Living Wage Member
Good Employment - Sponsor
Good Employment - Member
Armed Forces Covenant
Tech UK
IHSCM
FSB
Ban The Box
Stockport County
cpdgroup

Contact Details

Registered Address: Riverside House, Kings Reach Business Park, Yew Street, Stockport, SK4 2HD
Call Now: 0161 820 0631
Company Reg No. 11103622

Useful Links

Our Socials

Google Reviews
© Copyright 2025 All Rights Reserved - Convenzis